Clinical Trials
14
Active:0
Completed:0
Trial Phases
3 Phases
Phase 1:10
Phase 2:3
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Phase 1
10 (71.4%)Phase 2
3 (21.4%)Not Applicable
1 (7.1%)A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer
Not Applicable
Not yet recruiting
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-07-21
- Last Posted Date
- 2025-07-21
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT07076095
A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
Phase 2
Not yet recruiting
- Conditions
- NPCHNSCCRecurrenceMetastasis
- Interventions
- Biological: IAE0972+DocetaxelBiological: IAE0972+GemcitabineBiological: IAE0972+TaxanesBiological: IAE0972+Capecitabine
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06719479
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
Phase 1
Recruiting
- Conditions
- Advanced Malignant NeoplasmAdvanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT06581419
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06504732
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06292208
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China
- Prev
- 1
- 2
- 3
- Next
News
No news found